{"filings":[{"id":2108239,"accession_number":"0001388658-26-000071","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2026-08-06T21:15:31+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"iRhythm to acquire Vital Connect for $287.5M in cash and stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration $287.5M: $237.5M cash + $50M in iRhythm common stock.","Merger expected to close by end of 2026, subject to Vital Connect stockholder approval and HSR clearance.","iRhythm provides interim funding of up to $30M (initial $10M) to Vital Connect pre-close.","Reverse termination fee of $9M payable by iRhythm if deal fails due to antitrust issues.","Vital Connect will survive as a wholly owned subsidiary of iRhythm Technologies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2106156,"accession_number":"0001388658-26-000070","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2026-08-06T20:15:12+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"iRhythm Q2 revenue $224M (+20% YoY), raises guidance; acquires VitalConnect for $287.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Revenue $224.2M (+20.1% YoY); net loss $0.4M vs $14.2M loss; adjusted EBITDA $43.3M (19.3% margin).","FY2026 revenue guidance raised to $880-890M; adjusted EBITDA margin 13-14%.","Acquiring VitalConnect for ~$287.5M ($237.5M cash + $50M stock); expected close by end of 2026.","Settled Baxter patent litigation with $50M payment; cross-license and 6-year covenant not to sue.","FDA cleared third-gen algorithm; expected to cut clinician review time ~50% and save $100M over 5 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1057436,"accession_number":"0001388658-26-000055","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2026-06-15T20:30:17+00:00","items":["1.05"],"status":"ready","headline":"iRhythm discloses cyber incident with data exfiltration; threat actor demanded payment","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["Unauthorized activity identified June 8; threat actor demanded payment for not disclosing exfiltrated data including PHI and proprietary info.","Company determined incident material on June 10 due to volume of potentially affected data.","No impact to clinical/medical devices, financial reporting, or patient safety; no card info stored.","Investigation ongoing; no evidence of ongoing access; company believes not likely material to financial condition.","Company has cyber insurance but no assurance coverage sufficient."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":870556,"accession_number":"0001388658-26-000052","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2026-06-05T11:47:02+00:00","items":["7.01","9.01"],"status":"ready","headline":"iRhythm settles securities class action for $45M; expects insurance coverage for majority","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement payment of $45M to resolve putative class action securities lawsuit (Glazing Employers v. iRhythm Technologies).","Majority expected to be covered by D&O insurance; no remaining policy limits after payment.","No admission of fault; settlement subject to court approval; preliminary approval motion filed.","Does not resolve previously-disclosed stockholder derivative lawsuits.","Company expects no impact on adjusted EBITDA, adjusted net income, or adjusted operating expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":705036,"accession_number":"0001388658-26-000049","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2026-05-28T11:33:42+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"iRhythm shareholders approve 2026 equity plan, elect directors, remove pass-through voting provision","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected with strong support; no broker votes on most proposals.","2026 Equity Incentive Plan approved (26.8M for, 537K against), replacing the 2016 Plan.","Charter amendment to eliminate pass-through voting provision approved (27.3M for, 21.4K against).","KPMG ratified as FY2026 auditor (29.4M for, 16.8K against); say-on-pay approved non-binding.","Approximately 89.69% of outstanding shares represented, forming quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92561,"accession_number":"0001388658-26-000038","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q1 revenue $199.4M (+25.7%), net loss narrows; raises FY2026 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $199.4M, up 25.7% YoY; net loss $13.9M ($0.43/sh) vs $30.7M ($0.97/sh) in Q1 2025.","Adjusted EBITDA turned positive at $14.1M (7.1% margin) vs -$2.6M (-1.7%) a year ago; gross margin 70.9% up 210bps.","Raised FY2026 revenue guidance to $875M-$885M and adjusted EBITDA margin to 12%-13%.","Unrestricted cash $549.6M; presented data at ACC/HRS and launched new digital education platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":199390000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92560,"accession_number":"0001388658-26-000022","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"iRhythm dismisses PwC as auditor, hires KPMG for FY2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed PricewaterhouseCoopers LLP as independent auditor on March 30, 2026.","Audit reports for FY2024 and FY2025 contained no adverse opinion or modification.","Engaged KPMG LLP as new independent auditor for FY2026, effective March 30, 2026.","No disagreements or reportable events between PwC and the Company in the past two fiscal years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103485,"accession_number":"0001388658-26-000017","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"iRhythm appoints Jason Patten to board; $300K RSU grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Patten appointed director and Audit Committee member effective March 12, 2026.","Initial restricted stock unit grant valued at $300,000, vesting over three years.","Annual cash retainer of $55,000 for board service plus $10,000 for Audit Committee.","Patten previously served as advisor to CEO, receiving a one-time cash payment of $86,771.","Board determined Patten qualifies as independent under Nasdaq and SEC rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103484,"accession_number":"0001388658-26-000009","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm posts Q4 net income of $5.6M; first positive GAAP quarter; revenue +27% YoY; guides FY26 rev $870-880M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $208.9M (+27.1% YoY); GAAP net income $5.6M ($0.17 diluted EPS), first positive quarterly net income in company history.","Full year 2025 revenue $747.1M (+26.2%); net loss improved to $44.6M from $113.3M; first positive free cash flow of $34.5M.","Q4 adjusted EBITDA $34.3M (16.4% margin) vs $19.3M (11.7% margin) in Q4 2024; gross margin 70.9% (+90 bps).","FY2026 guidance: revenue $870-880M, adjusted EBITDA margin 11.5-12.5%.","Cash and marketable securities $583.8M at Dec 31, 2025; record quarterly revenue and fifth consecutive quarter >20% growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":747138000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103486,"accession_number":"0001104659-26-002755","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K12B","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","2.03","3.01","3.03","5.01","5.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"iRhythm completes holding company reorganization; new parent iRhythm Holdings successor issuer under IRTC","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Formed new parent iRhythm Holdings via merger of iRhythm into wholly owned sub; no stockholder vote required under DGCL Section 251(g).","Each share of iRhythm common stock converted 1:1 into iRhythm Holdings common stock; same ticker IRTC and CUSIP.","Executive officers and directors remain unchanged; equity awards and convertible notes assumed by iRhythm Holdings with adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119736,"accession_number":"0001388658-25-000219","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iRhythm issues fall 2025 shareholder outreach presentation; no material new details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished investor presentation as part of off-season proxy engagement program.","Presentation dated November 2025; no specific financial or operational updates provided in the filed exhibit excerpt.","Filing under Regulation FD; presentation is furnished, not filed.","No changes to guidance, strategy, or leadership were communicated in the available material."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119735,"accession_number":"0001388658-25-000216","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["1.01","5.02","2.02","9.01"],"status":"ready","headline":"iRhythm Q3 beat: rev $192.9M up 31% YoY, net loss narrows to $5.2M; FY25 guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $192.9M, up 30.7% YoY; gross margin 71.1% (+230bps).","Net loss of $5.2M ($0.16 diluted loss per share) vs $46.2M loss in Q3 2024.","Adjusted net loss $2.0M ($0.06 per share) vs $39.2M ($1.26) prior year.","FY2025 revenue guidance raised to $735M-$740M; adj. EBITDA margin 8.25-8.75%.","Board amended exec severance policy: enhanced change-of-control benefits; CEO gets 24 mo salary + 200% bonus + full equity acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":538248000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136309,"accession_number":"0001388658-25-000194","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q2 revenue up 26.1% to $186.7M; net loss narrows to $14.2M; raises FY 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $186.7M (+26.1% YoY); gross margin 71.2% (+130 bps).","Net loss $14.2M ($0.44/sh) improved from $20.1M loss ($0.65/sh) in Q2 2024.","Adjusted net loss $10.2M ($0.32/sh) improved from $18.8M loss ($0.61/sh) YoY.","FY 2025 guidance raised: revenue $720M-$730M; adj. EBITDA margin 8.0%-8.5%.","Unrestricted cash $545.5M; partnership with Lucem Health for AI-driven early disease detection."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":345364000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136308,"accession_number":"0001388658-25-000177","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"iRhythm board: Rubash and Snyderman retire; McGinnis and O'Boyle appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mark Rubash (board since 2016) and Ralph Snyderman (board since 2017) resigned effective July 7, 2025; no disagreement cited.","Karen McGinnis and Kevin O'Boyle appointed as directors effective July 7, 2025, both also join Audit Committee; O'Boyle also on Nominating & Governance.","Each new director granted RSUs with $300,000 fair value vesting over 3 years; annual cash retainers of $55k (board), $10k (audit), and $5k (governance for O'Boyle).","Board determined both new appointees qualify as independent under Nasdaq and SEC rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153429,"accession_number":"0001388658-25-000141","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"iRhythm shareholders elect all director nominees, ratify PwC as auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum of 30,038,591 shares (94.1% of eligible) present at May 28, 2025 annual meeting.","All eight director nominees elected: Blackford 28.2M for, Talwalkar 26.8M for, Bairey Merz 28.0M for, Bodaken 21.8M for, Ling 28.2M for, Rubash 27.5M for, Snyderman 28.1M for, Yoor 28.4M for.","Ratification of PricewaterhouseCoopers LLP as independent auditor for FY2025: 29,903,062 for, 132,424 against, 3,105 abstentions.","Advisory vote on named executive officer compensation approved: 27,454,502 for, 382,813 against, 774,141 abstentions.","All proposals passed with substantial majority; broker non-votes of 1,427,135 on director election and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153428,"accession_number":"0001388658-25-000105","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q1 revenue up 20% to $158.7M; raises FY 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $158.7M (+20.3% YoY); gross margin 68.8% (+250 bps).","Net loss narrowed to $30.7M ($0.97 diluted EPS) from $45.7M ($1.47) last year.","Adjusted net loss $30.3M ($0.95 diluted EPS) vs $38.1M ($1.23) in Q1 2024.","Cash $520.6M; raised FY25 revenue guidance to $690–700M and adj. EBITDA margin to 7.5–8.5%.","Operational: Zio AT strength, Japan commercial launch, studies showing LTCM superiority."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":158677000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172174,"accession_number":"0001388658-25-000026","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q4 revenue up 24% to $164.3M; net loss narrows to $1.3M; guides FY2025 revenue $675-685M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $164.3M (+24% YoY); gross margin 70.0% (+410bps). Net loss $1.3M vs $38.7M loss in Q4 2023.","Full year 2024 revenue $591.8M (+20.1%); net loss $113.3M vs $123.4M in 2023.","Adjusted EBITDA Q4 $19.3M (improvement of $16.9M); FY2024 adj EBITDA $(7.7)M.","Cash and marketable securities $535.6M at Dec 31, 2024; positive cash flow for three consecutive quarters.","2025 guidance: revenue $675-685M; adj EBITDA margin 7-8% of revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":591839000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172173,"accession_number":"0001388658-25-000005","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Mojdeh Poul to not seek re-election to iRhythm board at next annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mojdeh Poul notified iRhythm she will not stand for re-election when her current term expires.","Term ends on the date of the company's next annual meeting of stockholders.","Poul was recently appointed President and CEO of Integra LifeSciences (effective Jan 6, 2025).","Poul confirmed her decision is not based on any disagreement with iRhythm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172172,"accession_number":"0001388658-25-000003","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iRhythm pre-announces FY2024 revenue above guidance; FY2025 outlook $675M-$685M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY2024 revenue expected slightly above prior guidance of $587.5M (provided Oct 2024).","FY2025 revenue guidance of $675M-$685M, representing ~15% growth at midpoint.","Record Q4 new account openings for Zio monitor and Zio AT; strong national account volumes.","First four health systems launched on Epic Aura in Q4 2024; commercial rollout for Epic systems starts 2025.","Began Zio monitor shipments for home enrollment patients in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189156,"accession_number":"0001388658-24-000176","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["1.01","5.02","5.05","9.01"],"status":"ready","headline":"iRhythm removes evergreen provision from 2016 equity plan, amends Code of Conduct","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to 2016 Equity Incentive Plan removing automatic annual share increase (Evergreen Provision).","Maximum shares available for issuance as of Nov 7, 2024 is 5,169,736 plus shares from forfeited 2006 Plan awards.","Code of Conduct amended to modernize language, clarify manager responsibilities and policies on quality, privacy, security.","No waivers of prior Code provisions; revisions aim to support business and supply chain compliance.","Changes are governance-oriented; no financial impact from the plan amendment itself."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189155,"accession_number":"0001388658-24-000165","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q3 revenue $147.5M (+18% YoY); gross margin 68.8% up 260 bps","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $147.5M, up 18% YoY; gross profit $101.5M (+23%); gross margin 68.8% vs 66.2%","Record quarterly registration volume; record new account openings in US; UK billable registrations >10,000","FDA 510(k) clearance for Zio AT updates; commercial launch in Austria, Netherlands, Switzerland, Spain; Japan PMDA approval","Technology license agreement with BioIntelliSense for multi-sensor capabilities; recognized $32.1M IPR&D charge","Unrestricted cash $522.0M at Sep 30; cumulative one million patients registered for Zio monitor"],"consensus_eps_estimate":null,"consensus_eps_actual":-3.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":427514000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189154,"accession_number":"0001388658-24-000159","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iRhythm issues shareholder engagement presentation; no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation covers business overview, YTD accomplishments, governance, executive compensation, and sustainability.","No specific financial or operational metrics, guidance updates, or corporate events were disclosed.","Presentation is part of routine shareholder engagement program, not a material event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205638,"accession_number":"0001388658-24-000156","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"iRhythm licenses BioIntelliSense sensor tech for up to $35M + royalties; reaffirms FY2024 guidance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["iRhythm pays $15M upfront and up to $20M in milestone payments for an exclusive ACM license of pulse oximetry, accelerometry, and non-invasive BP tech.","Also purchased $40M in convertible notes from BioIntelliSense; $20M of Milestone Notes will be cancelled upon regulatory milestones.","Low single-digit royalties on home sleep testing product sales; license expires 10 years after first commercial sale per country.","iRhythm expects a non-recurring acquired IPR&D expense in 2024 but no material additional development costs; FY2024 revenue, gross margin, and adjusted EBITDA guidance reaffirmed.","Deal aims to expand iRhythm's ACM platform and enable entry into sleep apnea and other adjacent indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205637,"accession_number":"0001388658-24-000140","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"iRhythm Q2 revenue $148M (+19.3% YoY), raises FY24 guidance; names new CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $148.0M, up 19.3% YoY; gross margin 69.9% (+40 bps YoY).","Net loss $20.1M ($0.65 loss per share); adjusted net loss $18.8M ($0.61 per share).","Raised FY24 revenue guidance to $580-590M (18-20% growth); adj. EBITDA margin 3.5-4%.","CFO Brice Bobzien resigns effective Aug 31, 2024; succeeded by Daniel Wilson (EVP Corp Dev & IR)."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":279976000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222573,"accession_number":"0001388658-24-000106","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"iRhythm say-on-pay vote fails with majority against; all 9 directors re-elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Say-on-pay advisory proposal on NEO compensation rejected: 13.8M for vs 14.5M against.","All nine director nominees elected (Blackford, Talwalkar, Bairey Merz, Bodaken, Ling, Poul, Rubash, Snyderman, Yoor).","Ratification of PwC as independent auditor approved: 29.7M for, 113,942 against.","Amendment to charter to limit officer liability approved: 26.0M for, 2.3M against.","Frequency of future say-on-pay votes set to one year: 27.9M votes for 1 year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222572,"accession_number":"0001388658-24-000096","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q1 revenue $131.9M (+18.4% YoY); net loss widens to $45.7M; raises FY revenue guidance to $578-588M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $131.9M (+18.4% YoY); gross margin 66.3% (down 160 bps YoY).","Net loss $45.7M ($1.47/share) vs $39.1M ($1.29) YoY; adjusted loss $38.1M ($1.23) vs $33.4M ($1.10).","FY2024 revenue guidance raised to $578-588M (17-19% growth); gross margin 68-69%, adj. EBITDA margin 3-4%.","Over 500K registrations in Q1; announced Epic Aura collaboration for EMR integration; heart failure prediction data presented at ACC.","Unrestricted cash, equivalents, and marketable securities $569.1M as of March 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":131929000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242090,"accession_number":"0001193125-24-063728","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["1.01","8.01","2.03","3.02","9.01"],"status":"ready","headline":"iRhythm closes $661.25M convertible note offering, repays $80.2M existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $661.25M aggregate principal of 1.50% Convertible Senior Notes due 2029, including full $86.25M greenshoe exercise.","Net proceeds ~$643.6M; used ~$72.4M for capped call transactions, ~$80.2M to repay Braidwell term loan, and ~$25M to repurchase 229,252 shares at $109.05.","Notes have initial conversion price ~$147.22 (conversion rate 6.7927), with a cap of $218.10 per share.","Remaining proceeds for general corporate purposes including sales, R&D, and potential acquisitions.","Capped call transactions entered to reduce potential dilution on conversion; counterparties may hedge positions in IRTC shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242089,"accession_number":"0001193125-24-058503","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"iRhythm prices $575M convertible notes at 1.50%, upsized from $450M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$575M aggregate principal amount of 1.50% Convertible Senior Notes due 2029; upsized from $450M.","Initial conversion price ~$147.22/share, 35% premium over March 4 close of $109.05.","Net proceeds ~$559.5M; uses: repay $80.2M Braidwell debt, $63M capped calls, $25M share repurchase (229,252 shares).","Capped call transactions cap at $218.10/share to reduce potential dilution upon conversion.","Closing expected March 7, 2024; initial purchasers have 13-day option for additional $86.25M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242088,"accession_number":"0001193125-24-056762","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"iRhythm proposes $450M convertible senior notes due 2029; repays $80.1M Braidwell loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Offering $450M aggregate principal of 2029 convertible senior notes, plus $67.5M overallotment option.","Interest rate, conversion price and other terms to be set at pricing; notes are senior unsecured.","Net proceeds used to repay $80.1M Braidwell loan, repurchase up to $25M common stock, and for general corporate purposes.","Convertible at holders' option under certain conditions; settlement may be cash, stock, or combination.","Company expects to enter capped call transactions to reduce potential dilution upon conversion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242087,"accession_number":"0001388658-24-000013","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q4 rev $132.5M (+17.7% YoY); net loss $38.7M; FY2024 guidance $575-585M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $132.5M in Q4 2023, up 17.7% YoY; full-year revenue $492.7M, up 19.9%.","Net loss Q4 $38.7M ($1.26 diluted EPS), widened from $20.2M loss a year ago; FY loss $123.4M.","Gross margin fell to 66.0% in Q4 from 69.9% YoY, due to scaling costs and Zio monitor launch.","Adjusted EBITDA Q4 $2.4M (improved $1.3M); FY adjusted EBITDA -$4.9M, improved $6.4M.","FY2024 guidance: revenue ~$575-585M, gross margin 68-69%, adj. EBITDA margin 3-4%."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":492681000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242086,"accession_number":"0001388658-24-000006","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["1.01","1.02","7.01","9.01"],"status":"ready","headline":"iRhythm closes $150M Braidwell loan, Q4 registrations +22%, guides FY2024 rev ~$580M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed $150M Braidwell term loan (initial $75M funded, $75M delayed draw), interest margin 6.5-6.95%, matures Jan 2029, replaces SVB facility.","Preliminary Q4 2023 patient registrations grew >22% YoY.","Full year 2024 revenue guidance $575-585M, representing ~18-20% growth vs 2023 midpoint.","Submitted 510(k) for Zio AT system changes; received CE mark under EU MDR for Zio Monitor and ZEUS.","CAMELOT study in American Heart Journal shows higher clinical diagnostic yield and lower retesting odds with Zio LTCM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259496,"accession_number":"0001388658-23-000152","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"iRhythm amends bylaws for universal proxy rules and DGCL updates","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Revised advance notice bylaws requiring additional disclosures from proposing stockholders and nominees.","Added certification requirement that stockholders comply with SEC Rule 14a-19 universal proxy rules.","Updated notice provisions for electronic transmission of notices per DGCL amendments.","Added emergency bylaw provision allowing director quorum during an emergency situation.","Requires stockholders soliciting proxies to use a non-white proxy card color."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259495,"accession_number":"0001388658-23-000145","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q3 2023 revenue $124.6M (+20% YoY); raises FY2023 guidance to $487.5M-$490M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $124.6M (+20% YoY); net loss $27.1M ($0.89/share) vs $21.5M loss in prior year.","Gross margin 66.2%, down 210 bps due to reserves for excess Zio XT PCBA components.","Record registration volumes; launched next-generation Zio monitor with enhanced features.","FY2023 revenue guidance raised to $487.5M-$490M (~19% YoY growth); adj. EBITDA margin ~0%-0.5%.","Cash and marketable securities $158.5M as of Sept 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":360170000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276763,"accession_number":"0001388658-23-000119","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2023-08-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"iRhythm appoints Marc Rosenbaum as Chief Accounting Officer, effective August 11, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marc Rosenbaum, SVP Finance since May 2023, now also Chief Accounting Officer and principal accounting officer.","Previously served as VP, Corporate Controller and CAO at NuVasive (May 2022–May 2023).","Received equity grants totaling $1.2M (RSU and PSU) under the 2016 Plan, vesting over four years.","No additional compensation for the CAO role; no family relationships or material interests disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276762,"accession_number":"0001388658-23-000114","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"iRhythm grants performance-based RSUs to top executives with target shares and three-year goals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Blackford granted 48,534 target PSUs; CFO, CBLO, CCO, CMO each 13,589 target PSUs.","PSUs vest based on three equally weighted operational goals: patient registrations, adjusted EBITDA margin, product innovations over July 2023-June 2026.","Earned PSUs adjusted by TSR vs. S&P Healthcare Equipment Select Index; upward/downward 25% depending on percentile.","Maximum vesting at 150% of target if all three goals achieved and TSR above 75th percentile (capped).","Other management team members received aggregate 19,364 target PSUs under same program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276761,"accession_number":"0001388658-23-000102","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q2 revenue $124.1M (+21.6% YoY); narrows net loss; guides FY rev $485-490M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $124.1M, up 21.6% YoY; gross margin 69.5%, up 70 bps from 68.8%.","Net loss $18.5M ($0.61/share) vs $23.9M ($0.80) YoY; adjusted net loss $13.1M ($0.43).","Cash, equivalents, marketable securities $164.7M at June 30, 2023.","FY2023 guidance: revenue $485-490M (18-19% growth); gross margin 69-70%; adj. EBITDA ~0-0.5%.","Zio XT new account openings; Japan MHLW high medical needs designation; Shonin application filed."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":235566000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294563,"accession_number":"0001388658-23-000091","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CEO Quentin Blackford buys $1M worth of iRhythm shares in open market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["President and CEO Quentin Blackford purchased 9,755 shares of common stock on June 6, 2023.","Aggregate purchase price was approximately $1.0 million in open market transactions.","The purchase will be reported separately on a Form 4 filed with the SEC.","Insider buying signals management confidence in the company's prospects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294562,"accession_number":"0001388658-23-000087","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"iRhythm appoints Mojdeh Poul and Brian Yoor to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elected effective June 1, 2023; both will serve on the Audit Committee.","Each receives initial RSU grant of $300,000 vesting over three years.","Annual cash retainer: $50,000 for Board service, $10,000 for Audit Committee.","Board expands to nine directors, eight of whom are independent.","Poul and Yoor bring healthcare and financial leadership experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294561,"accession_number":"0001388658-23-000070","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA warning letter to iRhythm for Zio AT System quality and reporting violations","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA alleges non-conformities in medical device reporting and quality system requirements for Zio AT System.","Warning letter follows August 2022 inspection of iRhythm's Cypress, CA facility; company intends to respond within specified timeframe.","Company has taken corrective measures on prior FDA Form 483 observations and will continue remediation efforts.","Warning letter does not restrict manufacturing, production, or shipment of products in U.S. or require product withdrawal at this time.","iRhythm believes no material financial impact absent further adverse FDA action, but additional regulatory actions remain possible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294560,"accession_number":"0001388658-23-000067","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"iRhythm reports 2023 annual meeting results; all director nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected; Bruce Bodaken received 19,685,233 votes for (lowest margin).","Ratification of PwC as auditor approved: 29,174,545 for, 54,976 against, 11,118 abstain.","Advisory vote on executive compensation passed: 24,771,355 for, 2,982,847 against, 16,163 abstain.","Quorum of 29,240,639 shares (96% of eligible) present at May 24, 2023 meeting.","No broker non-votes on auditor ratification; all other proposals had 1,470,274 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294559,"accession_number":"0001388658-23-000048","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm reports Q1 revenue $111.4M (+20.6% YoY); updates FY2023 guidance to $480-$490M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $111.4M (+20.6% YoY); gross margin 67.9%, up 100 bps from 66.9%.","Net loss $39.1M ($1.29 loss per share) vs $50.6M ($1.71 loss per share) in Q1 2022.","Adjusted net loss $33.4M ($1.10 loss per share) vs $23.7M ($0.80 loss per share) in Q1 2022.","FY2023 revenue guidance raised to $480-$490M (17%-19% growth); gross margin 69%-70% expected.","CAMELOT study at ACC.23/WCC showed Zio XT highest diagnostic yield, lowest retesting rates."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":111436000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315173,"accession_number":"0001388658-23-000041","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"iRhythm COO Douglas Devine resigns; reaffirms 2023 revenue guidance of $475-485M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Douglas Devine resigned as COO on March 10, 2023; will serve as executive advisor through July 3, 2024.","Devine receives 12 months base salary severance, $69K bonus, and continued equity vesting under consulting agreement.","Daniel Wilson's role changes to EVP of Corporate Development and Investor Relations, dropping Corporate Strategy.","2023 revenue guidance reaffirmed at $475-485M, representing 16-18% growth over prior year.","Gross margin guidance 69-70%; adjusted EBITDA margin expected -0.5% to 0.5% of revenues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315172,"accession_number":"0001388658-23-000039","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"iRhythm updates cash position: $54.5M at SVB; affirms sufficient liquidity outside SVB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Held $54.5M in operating accounts at Silicon Valley Bank and $24.4M in money market funds outside SVB as of Dec 31, 2022.","Additional $134.3M in short-term investments (U.S. govt-backed) outside SVB; total cash, equivalents, short-term investments of $213.1M.","Has a $35M term loan with SVB that is not callable outside default; undrawn $40M term facility and $25M revolving credit line.","Affirms expectation that cash outside SVB is sufficient to meet requirements for foreseeable future."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315171,"accession_number":"0001388658-23-000006","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q4 revenue $112.6M (+37.7% YoY); adjusted EBITDA positive $1.1M; guides 2023 rev $475-485M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $112.6M (+37.7% YoY); gross margin 69.9% (up 720 bps); net loss $20.2M ($0.67 loss per share) vs $32.5M loss in Q4 2021.","Q4 adjusted EBITDA $1.1M, first positive quarter; full year adjusted EBITDA -$11.3M, improvement of $24.4M YoY.","Full year 2022 revenue $410.9M (+27.3% YoY); net loss $116.2M ($3.88 loss per share) vs $101.4M loss in 2021.","2023 guidance: revenue $475-485M (16-18% growth); gross margin 69-70%; adjusted EBITDA margin -0.5% to 0.5%.","Operational: CMS Final Rule with national CPT rates; FDA clearance for ZEUS system update; health economic data presented at AHA."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":410921000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333510,"accession_number":"0001388658-22-000149","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q3 revenue $103.9M (+21.6% YoY); cuts FY22 revenue guidance to $407-411M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $103.9M (+21.6% YoY); net loss $21.5M ($0.71/sh) vs $23.7M loss in Q3 2021.","Gross margin 68.3%, up 2.6pp from 65.7% in Q3 2021.","FY22 revenue guidance lowered to $407-411M from prior $415-420M (approx 26-27% YoY growth).","Adjusted EBITDA guidance improved to -$10 to -$12M from prior -$12.5 to -$17.5M; adjusted opex guidance $360-365M.","Registration volumes +22% YoY; highest daily registrations at Sept end; cited softness in returned devices persisting into Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":298304000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351005,"accession_number":"0001388658-22-000142","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2022-09-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iRhythm sets $1B revenue target by 2027, reaffirms FY2022 guidance, targets 15% EBITDA margin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirms FY2022 guidance: revenue $415-420M (29-30% growth), gross margin 68-69%, adjusted EBITDA loss $12.5-17.5M.","Sets 2027 goals: $1B+ revenue (~20% CAGR), gross margin ~73%, adjusted EBITDA margin ~15%.","Plans international expansion to 7 countries; introduces Know Your Rhythm early detection program with Heartbeat Health.","Targets $250M annual gross savings by 2027; expects continued innovation with Zio Monitor and ZEUS system.","Core business driven by cardiology and PCP expansion; served 4M patients with 30% revenue CAGR over 5 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351004,"accession_number":"0001388658-22-000126","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iRhythm Q2 revenue $102.1M (+26% YoY), raises FY22 guidance to $415-420M, loss widens","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $102.1M (+25.6% YoY); gross margin 68.8% (up 0.8pp).","Net loss $23.9M ($0.80 loss per share) vs $17.4M loss in Q2 2021.","FY22 revenue guidance raised to $415-420M (29-30% growth); adj. EBITDA loss guidance $(12.5)-$(17.5)M.","Cash $204.5M; record new account openings (+22% QoQ) and sequential revenue volume growth of 10%.","FDA 510(k) cleared Zio Watch (Verily partnership); CMS proposed reimbursement for Zio XT CPT codes."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":194429000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351003,"accession_number":"0001388658-22-000109","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2022-07-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"iRhythm appoints Brice Bobzien CFO (Aug 8); Reyna Fernandez CHRO; Devine stays COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Brice Bobzien as CFO effective Aug 8, 2022; Douglas Devine resigns as CFO but remains COO.","Appointed Reyna Fernandez as EVP, Chief Human Resources Officer effective July 25, 2022.","Bobzien's compensation: $400k base salary, 60% target bonus, $900k RSUs, $900k PSUs, Tier 2 severance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351002,"accession_number":"0001388658-22-000104","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2022-07-19T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"iRhythm CCO David Vort resigns; Chad Patterson appointed; Q2 volumes slightly ahead of guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Vort resigns as CCO effective July 25, 2022, will serve as strategic advisor through March 2023.","Chad Patterson named new CCO; previously Chief Marketing Officer at Dexcom with global growth experience.","Preliminary Q2 2022 unit volumes slightly ahead of expectations; FY 2022 revenue guidance unchanged at $410M-$420M.","Q2 2022 earnings call scheduled for August 4, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368227,"accession_number":"0001388658-22-000084","cik":1388658,"company_name":"iRhythm Holdings, Inc.","ticker":"IRTC","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"iRhythm elects six directors, ratifies PwC, approves say-on-pay at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six board nominees elected: Bairey Merz, Rubash, Budig, Talwalkar, Bodaken, Snyderman; each received >17.6M votes for.","Ratification of PwC as independent auditor approved with 28.2M for vs. 68k against.","Advisory say-on-pay approved with 22.6M for (83.8% of votes cast, excluding broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3714602232.3459916,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-06-02T23:59:59+00:00|368227"}